Maintenance pegylated liposomal doxorubicin versus observation for advanced soft tissue sarcoma after anthracycline control (MELODY)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an open-label, randomized Phase 2 trial for adults with advanced soft tissue sarcoma whose best response to first-line anthracycline-based therapy was complete response, partial response, or stable disease by RECIST 1.1. Participants are randomized to receive maintenance PLD 40 mg/m2 every 4 weeks for up to 12 cycles or to active surveillance (treatment holiday). Patients must have received 4–8 cycles of first-line anthracycline therapy, have at least one measurable lesion prior to first-line therapy, and be randomized within 8 weeks of their last anthracycline dose. The trial is conducted at multiple medical centers in Taiwan.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. A histologically confirmed advanced soft tissue sarcoma. Note that subtypes typically do not use chemotherapy as standard treatment are not allowed, such as alveolar soft part sarcoma, solitary fibrous tumor, extraskeletal myxoid chondrosarcoma, clear cell sarcoma)
2. Patients received first-line anthracycline-based treatment for a minimum of 4 cycles and a maximum of 8 cycles.
3. The best response after first-line anthracycline-based treatment must be either a complete response, partial response, or stable disease as defined by RECIST 1.1.

   The best response should be attributed solely to systemic treatment and not to local therapy. All the patients must have at least one measurable tumor based on RECIST 1.1 before initiating first-line anthracycline-based treatment.
4. Patients must be randomized within 8 weeks of their last dose of anthracycline-based treatment
5. Patients have a life expectancy ≥ 3 months
6. Patients older than 18 years old.
7. ECOG performance status of 0 to 1.
8. Patients must have adequate organ function and marrow reserve measured within 7 days prior to randomization as defined below:

   1. Hemoglobin ≥ 9.0 g/dL;
   2. Absolute neutrophil count ≥ 1,500/mm3;
   3. Platelets ≥ 100,000/mm3;
   4. Total bilirubin ≤ 1.5 x upper normal limit;
   5. AST(SGOT)/ALT(SGPT) ≤ 2.5 x upper normal limit; for patients with liver metastases AST(SGOT)/ALT(SGPT) ≤ 5 x upper normal limit is allowed;
   6. Serum creatinine ≤ 1.5mg/dL or creatinine clearance ≥50ml/min;
   7. All women of childbearing potential must have a negative pregnancy test obtained within 72 hours before starting therapy.
9. For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm.
10. Patients with reproductive potential must use effective contraception (hormone orbarrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 months after the completion of therapy.
11. Patients must be able to comply with study procedures and sign informed consent.

Exclusion Criteria:

1. Known allergy history to PLD or other drugs of liposome-based formulation.
2. LVEF \< 50% at screening as determined by UCG or MUGA.
3. Serious non-healing wound, ulcer, or bone fracture not related to underlying sarcoma.
4. Major surgical procedure, open biopsy, significant traumatic injury, or radiotherapy within 21 days prior to randomization.
5. Severe, uncontrolled medical conditions including severe liver disease, heart disease, uncontrolled diabetes or hypertension, or pulmonary disease.
6. Psychiatric illness or social situation that would preclude study compliance.
7. Women with pregnant or breast feeding (a urine pregnancy test must be performed on all female patients who are of childbearing potential before entering the study, and the result must be negative.
8. Another previous malignancy diagnosed within the past 3 years. Patients with carcinoma in situ and stage I malignancy under active surveillance (no medical treatment needed) are allowed for enrollment.
9. Active CNS metastasis defined by clinical symptoms, cerebral edema, steroid or anti- convulsant requirement, or progressive growth. Patients with a history of CNS metastasis or cord compression are allowed in the study if they have been treated and are clinically stable.
10. Patients with active hepatitis B. However, patients with controlled hepatitis B under anti-viral agent are allowed.

Where it's running

• Chang Gung Memorial Hospital
  Kaohsiung City, Taiwan Recruiting
• Kaohsiung Medical University Chung-Ho Memorial Hospital,
  Kaohsiung City, Taiwan Recruiting
• China Medical University Hospital
  Taichung, Taiwan Recruiting
• National Cheng Kung University Hospital
  Tainan, Taiwan Recruiting
• National Taiwan University Hospital
  Taipei, Taiwan Recruiting
• Taipei Veterans General Hospital
  Taipei, Taiwan Recruiting

Study contacts

• Principal investigator: Tom Wei-Wu Chen, MD,PhD — National Taiwan University Hospital
• Study coordinator: Hui-Jen Tsai, MD
• Email: hjtsai@nhri.edu.tw
• Phone: +886-6-7000123

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Polatuzumab Vedotin plus Rituximab with Reduced-dose chemo for frail seniors with DLBCL

  This trial tests whether a gentler, first-line treatment (Polatuzumab Vedotin with Rituximab and reduced-dose chemo) helps older, frail patients with DLBCL stay disease-free longer.

  Recruiting Phase 4 The First Hospital of Jilin University · Changchun, Jilin · NCT07908888

• Chemotherapy sensitivity-guided Culmerciclib combo for HR+/HER2- breast cancer before surgery

  This trial tests whether adding Culmerciclib to chemotherapy before surgery can help people with HR+/HER2- breast cancer who don’t respond to initial TAC treatment.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07900516

• Orelabrutinib plus Pola-R-CHP as first-line treatment for intermediate- to high-risk DLBCL

  This trial tests whether adding orelabrutinib to the Pola-R-CHP regimen can improve outcomes for adults with intermediate- to high-risk newly diagnosed DLBCL.

  Recruiting at 2 sites The First Affiliated Hospital of Xiamen University · Xiamen, Fujian and 1 other locations · NCT07778212

• Lifileucel (Tumor-infiltrating lymphocytes) for advanced soft tissue sarcoma

  This study tests lifileucel, a cell therapy made from a patient’s own tumor cells, in adults with unresectable or metastatic soft tissue sarcoma who have had prior treatments to see if it helps shrink tumors and improve outcomes.

  Recruiting at 2 sites Phase 2 Iovance Biotherapeutics, Inc. · Tampa, Florida and 1 other locations · NCT07741877

• Pyrotinib plus trastuzumab and chemotherapy for HER2-positive early breast cancer

  This study tests a treatment combination of Pyrotinib, Trastuzumab and chemo given before surgery to see if it can improve responses in HER2-positive breast cancer patients who have not yet been treated.

  Recruiting Phase 2 Hebei Medical University Fourth Hospital · Shijiazhuang, Hebei · NCT07635342

• Polatuzumab vedotin with Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in untreated DLBCL (MCD/BN2/N1)

  This study tests a targeted combination therapy to see if it can treat previously untreated DLBCL with specific molecular subtypes.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07608978

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.